The heterogeneous landscape of ALK negative ALCL. Review uri icon

Overview

abstract

  • Anaplastic Large Cell Lymphoma (ALCL) is a clinical and biological heterogeneous disease including systemic ALK positive and ALK negative entities. Whereas ALK positive ALCLs are molecularly characterized and readily diagnosed, specific immunophenotypic or genetic features to define ALK negative ALCL are missing, and their distinction from other T-cell non-Hodgkin lymphomas (T-NHLs) can be controversial. In recent years, great advances have been made in dissecting the heterogeneity of ALK negative ALCLs and in providing new diagnostic and treatment options for these patients. A new revision of the World Health Organization (WHO) classification promoted ALK negative ALCL to a definite entity that includes cytogenetic subsets with prognostic implications. However, a further understanding of the genetic landscape of ALK negative ALCL is required to dictate more effective therapeutic strategies specifically tailored for each subgroup of patients.

publication date

  • March 14, 2017

Research

keywords

  • Lymphoma, Large-Cell, Anaplastic
  • Receptor Protein-Tyrosine Kinases

Identity

PubMed Central ID

  • PMC5392347

Scopus Document Identifier

  • 85015221217

Digital Object Identifier (DOI)

  • 10.18632/oncotarget.14503

PubMed ID

  • 28061468

Additional Document Info

volume

  • 8

issue

  • 11